Skip to main content

PERSONALIZED ENGINE FOR CANCER INTEGRATIVE STUDY AND EVALUATION

Objective

Despite of their great promise, high-throughput technologies in cancer research have often failed to translate to major therapeutic advances in the clinic. One challenge has been tumour heterogeneity, where multiple competing subclones coexist within a single tumour. Genomic heterogeneity renders it difficult to identify all driving molecular alterations, and thus results in therapies that only target subsets of aggressive tumour cells. Another challenge lies in the integration of multiple types of molecular data into mathematical disease models that can make actionable clinical statements.

We aim to develop predictive computational technology that can exploit molecular and clinical data to improve our understanding of disease mechanisms and to inform clinicians about optimized strategies for therapeutic intervention. We propose to focus on prostate cancer, a leading cause of cancer death amongst men in Europe, but also prone to over-treatment. Our approach combines the exploitation of genomic, transcriptomic, proteomic, and clinical data in primary and metastatic tumours, prospective cohorts of well characterized prostate cancer patients, drug screenings in cell lines, and the use of the Watson technology, a last generation cognitive computer developed at IBM.

The translational objective of this study is to develop technology for identifying disease mechanisms and produce treatment recommendations for individual patients based on a therapeutic biomarker panel. The proposed software framework will be accessible through a graphical interface that will facilitate its dissemination and use by researchers, clinicians, and biomedical industries. The framework will provide intuitive tools to deposit, share, analyze, and visualize molecular and clinical data; as well as to infer prognosis, elucidate implicated mechanisms and recommend therapy accordingly. This software framework will serve as a proof of concept for future development by industrial partners in Europe.

Field of science

  • /natural sciences/computer and information sciences/software
  • /medical and health sciences/clinical medicine/oncology/cancer
  • /medical and health sciences/clinical medicine/oncology/cancer/prostate cancer

Call for proposal

H2020-PHC-2015-two-stage
See other projects for this call

Funding Scheme

RIA - Research and Innovation action
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

TECHNIKON FORSCHUNGS- UND PLANUNGSGESELLSCHAFT MBH
Address
Burgplatz 3A
9500 Villach
Austria
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 358 125

Participants (8)

IBM RESEARCH GMBH
Switzerland
EU contribution
€ 0
Address
Saeumerstrasse 4
8803 Rueschlikon
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
TECHNISCHE UNIVERSITAT DARMSTADT
Germany
EU contribution
€ 539 375
Address
Karolinenplatz 5
64289 Darmstadt
Activity type
Higher or Secondary Education Establishments
UNIVERSITAETSKLINIKUM AACHEN
Germany
EU contribution
€ 620 937,50
Address
Pauwelsstrasse 30
52074 Aachen
Activity type
Higher or Secondary Education Establishments
EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH
Switzerland
EU contribution
€ 0
Address
Raemistrasse 101
8092 Zuerich
Activity type
Higher or Secondary Education Establishments
UNIVERSITAT ZURICH
Switzerland
EU contribution
€ 0
Address
Ramistrasse 71
8006 Zurich
Activity type
Higher or Secondary Education Establishments
BAYLOR COLLEGE OF MEDICINE
United States
EU contribution
€ 561 250
Address
One Baylor Plaza T119
77030 Houston Tx
Activity type
Higher or Secondary Education Establishments
INSTITUT CURIE
France
EU contribution
€ 535 625
Address
Rue D'ulm 26
75231 Paris
Activity type
Research Organisations
ASTRIDBIO TECHNOLOGIES KFT
Hungary
EU contribution
€ 475 000
Address
Also Kikoto Sor 11D
6726 Szeged
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)